Could an Immune-Suppressing drug treat some forms of schizophrenia?

This study tests whether ocrelizumab, a drug that suppresses certain immune cells, can reduce psychosis symptoms in people whose schizophrenia or bipolar disorder may be caused by auto-antibodies attacking brain receptors. Forty participants aged 18–35 will receive either ocrelizumab or a placebo, and their symptoms will be measured using standard psychiatric scales. The goal is to see if targeting the immune system can improve outcomes for this specific subgroup.